Evidence map›Paper›PMID 42589898›Full record

ArticleJournal of clinical medicine2026

Exploratory Study of Clinical Factors Associated with MPO-ANCA Positivity in Nontuberculous Mycobacterial Pulmonary Disease.

Hidenori Takahashi, Yugo Satake, Takumi Yasuda, Kota Taguchi, Kanako Furukawa, Hiroki Nagamatsu, Ryutaro Hirose, Naoya Toba, Mio Toyama-Kousaka, Shinichiro Ota and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hidenori TakahashiDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.ORCID 0000-0001-9781-258X
Yugo SatakeDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
Takumi YasudaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
Kota TaguchiDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
Kanako FurukawaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
Hiroki NagamatsuDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
Ryutaro HiroseDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
Naoya TobaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
Mio Toyama-KousakaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
Shinichiro OtaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.ORCID 0000-0002-0922-8656
Miwa MorikawaDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
Masaharu ShinkaiDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

methodsThis study retrospectively analyzed patients aged ≥15 years old with NTM-PD who were treated at Tokyo Shinagawa Hospital and underwent MPO-ANCA testing between April 2020 and March 2024. Clinical data, including nontuberculous mycobacterial species, serum

resultsAmong 109 patients with NTM-PD, 49 underwent testing for MPO-ANCA and proteinase 3 (PR3)-ANCA. MPO-ANCA was positive in five patients (10.2%), whereas PR3-ANCA was positive in one (2.0%). Among the five MPO-ANCA-positive patients, three had MAC antibody titers above the upper limit of measurement (>10 U/mL), and one developed AAV with biopsy-proven pauci-immune crescentic glomerulonephritis and mononeuritis multiplex. The MAC antibody titer was significantly higher in the MPO-ANCA-positive group than in the MPO-ANCA-negative group [10.0 (3.89-10.0) vs. 1.92 (0.19-6.19) U/mL,

conclusionsMPO-ANCA positivity was observed in a subset of tested patients with NTM-PD and was associated with higher MAC antibody titers. These findings suggest that chronic MAC-related antigen exposure or local pulmonary disease activity in NTM-PD may be associated with MPO-ANCA positivity.

Indexed as

ANCA-associated vasculitisMAC antibodyMPO-ANCAMycobacterium avium complexnontuberculous mycobacterial pulmonary disease

Identifiers

PMID42589898
PMCPMC13467360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.